Abbott Labs Surges on Cancer Test Win | Business and Finance News

Abbott Labs just crushed it—boosting its annual profit forecast and sending shares soaring thanks to its $21B Exact Sciences acquisition, which added top-tier cancer screening tools to its arsenal. Diagnostics sales jumped 40% and glucose monitors drove medical devices growth, while EPS rose 4%—beating Wall Street. With a 54-year dividend streak and 2026 sales growth projected at 6.5–7.5%, Abbott’s momentum is undeniable. But as always, do your homework—other stocks are heating up too. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/0927db412a4c2c7e